KYMR vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 05, 2026

KYMR

30.7
AI Score
VS
MRNA Wins

MRNA

48.5
AI Score

Investment Advisor Scores

KYMR

31score
Recommendation
AVOID NEW MONEY

MRNA

49score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric KYMR MRNA Winner
Forward P/E 0 23.0415 Tie
PEG Ratio 0 0 Tie
Revenue Growth 466.4% 2.1% KYMR
Earnings Growth 0.0% -85.1% KYMR
Tradestie Score 30.7/100 48.5/100 MRNA
Profit Margin 0.0% -141.4% KYMR
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD MRNA

Relative Price Performance (Last 90 Days)

KYMR 1M: +21.0% · 3M: +10.2% MRNA 1M: +7.8% · 3M: +285.2%

Current Technical Phase

KYMR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.7% over 20 days), RSI 57

RSI (14): 57.1 · Price: $129.31

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (32.2% over 20 days), RSI 57

RSI (14): 57.0 · Price: $243.93

Fundamentals Snapshot

Metric KYMR MRNA
Market Cap — —
Forward P/E -26.4 -56.5
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 4.7% 0.3%
Gross Margin -3.2% -0.4%
Operating Margin -4.0% 0.1%
EPS -3.64 -6.56
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.